Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1978 1
1981 1
1985 1
1988 2
1992 1
1993 2
1994 2
1995 8
1996 2
1997 2
1998 2
2002 2
2003 1
2004 3
2005 2
2006 4
2007 7
2008 5
2009 2
2010 1
2012 1
2013 6
2014 6
2015 4
2016 5
2017 3
2018 6
2019 1
2020 7
2021 5
2022 1
2023 5
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

97 results

Results by year

Filters applied: . Clear all
Page 1
Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors.
Hendry S, Salgado R, Gevaert T, Russell PA, John T, Thapa B, Christie M, van de Vijver K, Estrada MV, Gonzalez-Ericsson PI, Sanders M, Solomon B, Solinas C, Van den Eynden GGGM, Allory Y, Preusser M, Hainfellner J, Pruneri G, Vingiani A, Demaria S, Symmans F, Nuciforo P, Comerma L, Thompson EA, Lakhani S, Kim SR, Schnitt S, Colpaert C, Sotiriou C, Scherer SJ, Ignatiadis M, Badve S, Pierce RH, Viale G, Sirtaine N, Penault-Llorca F, Sugie T, Fineberg S, Paik S, Srinivasan A, Richardson A, Wang Y, Chmielik E, Brock J, Johnson DB, Balko J, Wienert S, Bossuyt V, Michiels S, Ternes N, Burchardi N, Luen SJ, Savas P, Klauschen F, Watson PH, Nelson BH, Criscitiello C, O'Toole S, Larsimont D, de Wind R, Curigliano G, André F, Lacroix-Triki M, van de Vijver M, Rojo F, Floris G, Bedri S, Sparano J, Rimm D, Nielsen T, Kos Z, Hewitt S, Singh B, Farshid G, Loibl S, Allison KH, Tung N, Adams S, Willard-Gallo K, Horlings HM, Gandhi L, Moreira A, Hirsch F, Dieci MV, Urbanowicz M, Brcic I, Korski K, Gaire F, Koeppen H, Lo A, Giltnane J, Rebelatto MC, Steele KE, Zha J, Emancipator K, Juco JW, Denkert C, Reis-Filho J, Loi S, Fox SB. Hendry S, et al. Adv Anat Pathol. 2017 Nov;24(6):311-335. doi: 10.1097/PAP.0000000000000161. Adv Anat Pathol. 2017. PMID: 28777143 Free PMC article. Review.
In part 1 of this review, we have proposed a standardized methodology to assess tumor-infiltrating lymphocytes (TILs) in solid tumors, based on the International Immuno-Oncology Biomarkers Working Group guidelines for invasive breast carcinoma. In part 2 of this review, we …
In part 1 of this review, we have proposed a standardized methodology to assess tumor-infiltrating lymphocytes (TILs) in solid tumors, based …
High-grade Endometrial Carcinomas: Morphologic and Immunohistochemical Features, Diagnostic Challenges and Recommendations.
Murali R, Davidson B, Fadare O, Carlson JA, Crum CP, Gilks CB, Irving JA, Malpica A, Matias-Guiu X, McCluggage WG, Mittal K, Oliva E, Parkash V, Rutgers JKL, Staats PN, Stewart CJR, Tornos C, Soslow RA. Murali R, et al. Int J Gynecol Pathol. 2019 Jan;38 Suppl 1(Iss 1 Suppl 1):S40-S63. doi: 10.1097/PGP.0000000000000491. Int J Gynecol Pathol. 2019. PMID: 30550483 Free PMC article. Review.
FIGO grade 3 endometrioid carcinoma is diagnosed when an endometrioid carcinoma exhibits >50% solid architecture (excluding squamous areas), or when an architecturally FIGO grade 2 endometrioid carcinoma exhibits marked cytologic atypia, provided that a gl …
FIGO grade 3 endometrioid carcinoma is diagnosed when an endometrioid carcinoma exhibits >50% solid architecture (excluding …
Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group.
Mosele F, Remon J, Mateo J, Westphalen CB, Barlesi F, Lolkema MP, Normanno N, Scarpa A, Robson M, Meric-Bernstam F, Wagle N, Stenzinger A, Bonastre J, Bayle A, Michiels S, Bièche I, Rouleau E, Jezdic S, Douillard JY, Reis-Filho JS, Dienstmann R, André F. Mosele F, et al. Ann Oncol. 2020 Nov;31(11):1491-1505. doi: 10.1016/j.annonc.2020.07.014. Epub 2020 Aug 24. Ann Oncol. 2020. PMID: 32853681 Free article. Review.
Based on the current evidence, ESMO recommends routine use of NGS on tumour samples in advanced non-squamous non-small-cell lung cancer (NSCLC), prostate cancers, ovarian cancers and cholangiocarcinoma. ...In addition, based on the KN158 trial and considering that p …
Based on the current evidence, ESMO recommends routine use of NGS on tumour samples in advanced non-squamous non-small-cell lu …
Exploiting the folate receptor α in oncology.
Scaranti M, Cojocaru E, Banerjee S, Banerji U. Scaranti M, et al. Nat Rev Clin Oncol. 2020 Jun;17(6):349-359. doi: 10.1038/s41571-020-0339-5. Epub 2020 Mar 9. Nat Rev Clin Oncol. 2020. PMID: 32152484 Review.
Furthermore, using FRalpha to better localize effective anticancer therapies to their target tumours using platforms such as antibody-drug conjugates, small-molecule drug conjugates, radioimmunoconjugates and, more recently, chimeric antigen receptor T cells could further …
Furthermore, using FRalpha to better localize effective anticancer therapies to their target tumours using platforms such as antibody-drug c …
Programmed death ligand-1 (PD-L1) as a predictive marker for immunotherapy in solid tumours: a guide to immunohistochemistry implementation and interpretation.
Paver EC, Cooper WA, Colebatch AJ, Ferguson PM, Hill SK, Lum T, Shin JS, O'Toole S, Anderson L, Scolyer RA, Gupta R. Paver EC, et al. Pathology. 2021 Feb;53(2):141-156. doi: 10.1016/j.pathol.2020.10.007. Epub 2020 Dec 30. Pathology. 2021. PMID: 33388161 Review.
Immunotherapy with checkpoint inhibitors is well established as an effective treatment for non-small cell lung cancer and melanoma. The list of approved indications for treatment with PD-1/PD-L1 checkpoint inhibitors is growing rapidly as clinical trials continue to …
Immunotherapy with checkpoint inhibitors is well established as an effective treatment for non-small cell lung cancer and mela …
Role of miR-424 in the carcinogenesis.
Ghafouri-Fard S, Askari A, Hussen BM, Taheri M, Akbari Dilmaghani N. Ghafouri-Fard S, et al. Clin Transl Oncol. 2024 Jan;26(1):16-38. doi: 10.1007/s12094-023-03209-2. Epub 2023 May 13. Clin Transl Oncol. 2024. PMID: 37178445 Free PMC article. Review.
Experiments in the ovarian cancer, cervical cancer, hepatocellular carcinoma, neuroblastoma, breast cancer, osteosarcoma, intrahepatic cholangiocarcinoma, prostate cancer, endometrial cancer, non-small cell lung cancer, hemangioma and gastric cancer ha …
Experiments in the ovarian cancer, cervical cancer, hepatocellular carcinoma, neuroblastoma, breast cancer, osteosarcoma, intrahepati …
Small cell carcinoma of the gynecologic tract: a multifaceted spectrum of lesions.
Atienza-Amores M, Guerini-Rocco E, Soslow RA, Park KJ, Weigelt B. Atienza-Amores M, et al. Gynecol Oncol. 2014 Aug;134(2):410-8. doi: 10.1016/j.ygyno.2014.05.017. Epub 2014 May 27. Gynecol Oncol. 2014. PMID: 24875120 Review.
OBJECTIVE: Small cell carcinoma (SmCC) of the female genital tract constitutes a diagnostic and clinical challenge given its rarity and the lack of standardized therapeutic approaches. ...CONCLUSIONS: Despite the potential differences in etiology and risk fac …
OBJECTIVE: Small cell carcinoma (SmCC) of the female genital tract constitutes a diagnostic and clinical challenge give …
HAND2-AS1: A functional cancer-related long non-coding RNA.
Gu X, Zheng Q, Chu Q, Zhu H. Gu X, et al. Biomed Pharmacother. 2021 May;137:111317. doi: 10.1016/j.biopha.2021.111317. Epub 2021 Feb 5. Biomed Pharmacother. 2021. PMID: 33556872 Free article. Review.
The lncRNA heart and neural crest derivatives expressed transcript 2 antisense RNA 1 (HAND2-AS1) suppresses tumor growth, and its expression level was lower in tumor tissues than in adjacent normal tissues of most types of human cancers, including non-small cell lun …
The lncRNA heart and neural crest derivatives expressed transcript 2 antisense RNA 1 (HAND2-AS1) suppresses tumor growth, and its expression …
ARID1A gene mutation in ovarian and endometrial cancers (Review).
Takeda T, Banno K, Okawa R, Yanokura M, Iijima M, Irie-Kunitomi H, Nakamura K, Iida M, Adachi M, Umene K, Nogami Y, Masuda K, Kobayashi Y, Tominaga E, Aoki D. Takeda T, et al. Oncol Rep. 2016 Feb;35(2):607-13. doi: 10.3892/or.2015.4421. Epub 2015 Nov 16. Oncol Rep. 2016. PMID: 26572704 Free PMC article. Review.
ARID1A mutations have been found in various types of cancer and occur at high frequency in endometriosis-associated ovarian cancer, including clear cell adenocarcinoma and endometrioid adenocarcinoma, and also occur at endometrial cancer especially in endometrioid a …
ARID1A mutations have been found in various types of cancer and occur at high frequency in endometriosis-associated ovarian cancer, includin …
97 results